ArticleFrontiers in medicine2026
Predicting membranous nephropathy remission: a nomogram based on early dynamic biomarkers.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Traditional prognostic assessment of membranous nephropathy (MN) relies on baseline static indicators, which do not allow for the dynamic monitoring of early treatment response. This study aims to evaluate whether early changes in anti-PLA2R antibody titers, 24-h urine protein quantification, and serum albumin levels can predict 12-month remission and to develop a nomogram model to facilitate clinical decision-making. Methods: A retrospective analysis was conducted on 144 patients with PLA2R-related MN treated with rituximab between 2022 and 2025. Patients were categorized into remission ( Results: At 1 month post-treatment, non-remission patients demonstrated a significantly lower percentage decline in anti-PLA2R antibodies (47.26% vs. 85.74%, Conclusion: Dynamic changes in anti-PLA2R antibodies, urinary protein, and serum albumin at 1 month are effective predictors of 12-month remission in MN. This nomogram model enables early risk stratification and the optimization of personalized treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.